Literature DB >> 9127224

Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.

M M McDermott1, S Mehta, H Ahn, P Greenland.   

Abstract

OBJECTIVE: To compare rates of therapy for atherosclerotic risk factors between patients with lower extremity peripheral arterial disease (PAD) and patients with coronary artery disease (CAD).
DESIGN: Cross-sectional.
SETTING: Academic medical center. PATIENTS/PARTICIPANTS: Three hundred forty-nine consecutive patients diagnosed with PAD or CAD identified from the blood flow and cardiac catheterization laboratories, respectively.
MEASUREMENTS AND MAIN RESULTS: Participants were interviewed by telephone for medical history as well as therapies prescribed and recommended by their physicians. Among patients with hypercholesterolemia, more CAD patients were taking cholesterol-lowering drugs (58% vs 46%, p = .08) and more CAD patients recalled a physician's instruction to follow a low-fat, low-cholesterol diet (94% vs 83%, p = .01). CAD patients were more likely to exercise regularly (71% vs 50%, p < .01). Among patients not exercising, more CAD patients recalled a physician's advice to exercise (74% vs 47%, p < .01). In logistic regression analysis, hypercholesterolemic patients with exclusive CAD were more likely to be treated with drug therapy (odds ratio [OR] 2.3, p = .05). CAD patients were more likely to recall advice to exercise (OR 4.0, p < .001), and more likely to be taking aspirin or warfarin (OR 4.8, p = .01).
CONCLUSIONS: Atherosclerotic risk factors are less intensively treated among PAD patients than CAD patients. A number of possible explanations could account for these disparities in therapeutic intensity.

Entities:  

Mesh:

Year:  1997        PMID: 9127224      PMCID: PMC1497093          DOI: 10.1046/j.1525-1497.1997.012004209.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  27 in total

1.  Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.

Authors:  G A Lamas; M A Pfeffer; P Hamm; J Wertheimer; J L Rouleau; E Braunwald
Journal:  N Engl J Med       Date:  1992-07-23       Impact factor: 91.245

2.  Preventing heart attack and death in patients with coronary disease.

Authors:  S C Smith; S N Blair; M H Criqui; G F Fletcher; V Fuster; B J Gersh; A M Gotto; K L Gould; P Greenland; S M Grundy
Journal:  Circulation       Date:  1995-07-01       Impact factor: 29.690

Review 3.  Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.

Authors:  V Fuster; M L Dyken; P S Vokonas; C Hennekens
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

4.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

5.  Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators.

Authors:  J B Cavender; W J Rogers; L D Fisher; B J Gersh; C J Coggin; W O Myers
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

6.  Decreased ankle/arm blood pressure index and mortality in elderly women.

Authors:  M T Vogt; J A Cauley; A B Newman; L H Kuller; S B Hulley
Journal:  JAMA       Date:  1993-07-28       Impact factor: 56.272

Review 7.  Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18-20, 1992 New Orleans, Louisiana.

Authors:  T J Orchard; D E Strandness
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

8.  The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys.

Authors:  G C Leng; F G Fowkes
Journal:  J Clin Epidemiol       Date:  1992-10       Impact factor: 6.437

9.  Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index.

Authors:  A B Newman; K Sutton-Tyrrell; M T Vogt; L H Kuller
Journal:  JAMA       Date:  1993-07-28       Impact factor: 56.272

Review 10.  Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

Authors:  B G Brown; X Q Zhao; D E Sacco; J J Albers
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more
  37 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Delayed calf muscle phosphocreatine recovery after exercise identifies peripheral arterial disease.

Authors:  David C Isbell; Stuart S Berr; Alicia Y Toledano; Frederick H Epstein; Craig H Meyer; Walter J Rogers; Nancy L Harthun; Klaus D Hagspiel; Arthur Weltman; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2006-05-15       Impact factor: 24.094

3.  Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease.

Authors:  Meggan R Banta; Fangchao Ma; Dawn M Bravata; Robert S Kirsner; Daniel G Federman
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

4.  Peripheral artery disease: current insight into the disease and its diagnosis and management.

Authors:  Jeffrey W Olin; Brett A Sealove
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

5.  Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey.

Authors:  Mary McGrae McDermott; Elizabeth A Hahn; Philip Greenland; David Cella; Judith K Ockene; Donna Brogan; William H Pearce; Alan T Hirsch; Kendra Hanley; Linda Odom; Shaheen Khan; Michael H Criqui; Martin S Lipsky; Stacie Hudgens
Journal:  J Gen Intern Med       Date:  2002-12       Impact factor: 5.128

6.  The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.

Authors:  Kelly P Downing; Kevin T Nead; Yoko Kojima; Themistocles Assimes; Lars Maegdefessel; Thomas Quertermous; John P Cooke; Nicholas J Leeper
Journal:  Vasc Med       Date:  2013-12-09       Impact factor: 3.239

7.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.

Authors:  Dharam J Kumbhani; Ph Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Shinya Goto; E Magnus Ohman; Yedid Elbez; Piyamitr Sritara; Iris Baumgartner; Subhash Banerjee; Mark A Creager; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

8.  Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease.

Authors:  Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen
Journal:  Clin Cardiol       Date:  2018-10-19       Impact factor: 2.882

9.  Nutritional status and body composition in patients with peripheral arterial disease: A cross-sectional examination of disease severity and quality of life.

Authors:  Diana P Brostow; Alan T Hirsch; Mark A Pereira; Robin L Bliss; Mindy S Kurzer
Journal:  Ecol Food Nutr       Date:  2015-12-11       Impact factor: 1.692

10.  Self-reported peripheral arterial disease predicts future vascular events in a community-based cohort.

Authors:  Maya J Salameh; Tatjana Rundek; Bernadette Boden-Albala; Zhezhen Jin; Elizabeth V Ratchford; Marco R Di Tullio; Shunichi Homma; Ralph L Sacco
Journal:  J Gen Intern Med       Date:  2008-06-25       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.